1887

Abstract

A recombinant vaccinia virus containing most of the P1 region of hepatitis A virus (HAV) was constructed. Cell lysates of cultures infected with the virus contained HAV proteins detectable by radioimmunoassay. Western blot analysis revealed the presence of a single protein of 60K to 62K, bearing epitopes from structural polypeptides VP4, -3 and -2, and the N terminus of VP1. The size of the protein suggests that at least some of the vaccinia virus thymidine kinase is also expressed. Inoculation of tamarin monkeys with the recombinant virus resulted in the development of a specific anti-HAV immune response which was protective against challenge with a virulent strain of HAV. Recombinant viruses expressing the above region of HAV or the proteins expressed by such viruses may be useful in the development of a vaccine suitable for use in man.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-72-9-2167
1991-09-01
2021-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jgv/72/9/JV0720092167.html?itemId=/content/journal/jgv/10.1099/0022-1317-72-9-2167&mimeType=html&fmt=ahah

References

  1. Binn L. N., Bancroft W. H., Lemon S. M., Marchwicki R. H., LeDuc J. W., Trahan C. J., Staley E. C., Keenan C. M. 1986; Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. Journal of Infectious Diseases 153:749–756
    [Google Scholar]
  2. Cohen J. I., Ticehurst J. R., Purcell R. H., Buckler-White A., Baroudy B. M. 1987; Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. Journal of Virology 61:50–59
    [Google Scholar]
  3. Elango N., Prince G. A., Murphy B. R., Venkatesan S., Chanock R. M., Moss B. 1986; Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing RSV G glycoprotein. Proceedings of the National Academy of Sciences, U.S.A. 83:1906–1910
    [Google Scholar]
  4. Emini E. A., Hughes J. V., Perlow D. S., Roger J. 1985; Induction of hepatitis A virus neutralizing antibody by a virus-specific synthetic peptide. Journal of Virology 55:836–839
    [Google Scholar]
  5. Feinstone S. M., Daemer R. J., Gust I. D., Purcell R. H. 1983; Live attenuated vaccine for hepatitis A. Developments in Biological Standardization 54:429–432
    [Google Scholar]
  6. Flehmig B., Heinricy U., Pfisterer M. 1989; Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet i:1039–1041
    [Google Scholar]
  7. Hughes J. V., Stanton L. W., Tomassini J. E., Long W. J., Scolnick E. M. 1984; Neutralizing monoclonal antibodies to hepatitis A virus: partial localization of a neutralizing antigenic site. Journal of Virology 52:465–473
    [Google Scholar]
  8. Johnston J. M., Harmon S. A., Binn L. N., Richards O. C., Ehrenfeld E., Summers D. F. 1988; Antigenic and immunogenic properties of a hepatitis A virus capsid protein expressed in Escherichia coli. Journal of Infectious Diseases 157:1203–1211
    [Google Scholar]
  9. Karayiannis P., Jowett T., Enticott M., Pignatelli M., Brenes F., Scheuer P. J., Thomas H. C. 1986; Hepatitis A virus replication in tamarins and host immune response in relation to pathogenesis of liver cell damage. Journal of Medical Virology 18:261–276
    [Google Scholar]
  10. Karayiannis P., McGarvey M. J., Fry M. A., Thomas H. C. 1988; Detection of hepatitis A virus RNA in tissues and faeces of experimentally infected tamarins by cDNA hybridization. In Viral Hepatitis and Liver Disease pp 117–120 Edited by Zuckerman A. J. New York: Alan R. Liss;
    [Google Scholar]
  11. Karron R. A., Daemer R., Ticehurst J., D’Hondt E., Popper H., Mihalik K., Phillips J., Feinstone S., Purcell R. H. 1988; Studies of prototype live hepatitis A virus vaccines in primate models. Journal of Infectious Diseases 157:338–345
    [Google Scholar]
  12. Kieny M. P., Lathe R., Drillien R., Spenher D., Skory S., Schmitt D., Wiktor T., Koprowski H., Lecocq J. P. 1984; Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature, London 312:163–166
    [Google Scholar]
  13. Mackett M., Smith G. L., Moss B. J. 1984; General method for the production and selection of infectious vaccinia virus recombinants expressing foreign genes. Virology 49:857–864
    [Google Scholar]
  14. Mackett M., Yilma T., Rose J., Moss B. 1985a; Vaccinia virus recombinants: expression of VSV genes and protective inmmunization of mice and cattle. Science 227:433–435
    [Google Scholar]
  15. Mackett M., Smith G. L., Moss B. 1985b; The construction and characterisation of vaccinia virus recombinants expressing foreign genes. In DNA Cloning: A Practical Approach pp 191–211 Edited by Glover D. M. Oxford & Washington, D.C.: IRL Press;
    [Google Scholar]
  16. Mao J. S., Dong D. X., Zhang H. Y., Chen N. L., Zhang X. Y., Huang H. Y., Xie R. Y., Zhou T. J., Wan Z. J., Wang Y. Z., Hu Z. H., Cao Y. Y., Li H. M., Chu C. M. 1989; Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. Journal of Infectious Diseases 159:621–624
    [Google Scholar]
  17. Moss B., Smith G. L., Gerin J. L., Purcell R. H. 1984; Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature, London 311:67–69
    [Google Scholar]
  18. Ping L. H., Jansen R. W., Stapleton J. T., Cohen J. I., Lemon S. M. 1988; Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus. Proceedings of the National Academy of Sciences, U.S.A 85:8281–8285
    [Google Scholar]
  19. Provost P. J., Hilleman M. R. 1978; An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proceedings of the Society of Experimental Biology and Medicine 159:201–203
    [Google Scholar]
  20. Provost P. J., Banker F. S., Giesa P. A., McAleer W. J., Buynak E. B., Hilleman M. R. 1982; Progress towards a live, attenuated human hepatitis A virus vaccine. Proceedings of the Society for Experimental Biology and Medicine 170:8–14
    [Google Scholar]
  21. Provost P. J., Conti P. A., Giesa P. A., Banker F. S., Buynak E. B., McAleer W. J., Hilleman M. R. 1983; Studies in chimpanzees of live attenuated hepatitis A vaccine candidates. Proceedings of the Society for Experimental Biology and Medicine 172:357–363
    [Google Scholar]
  22. Provost P. J., Bishop R. J., Gerety R. J., Hilleman M. R., McAleer W. J., Scolnick E. M., Stevens C. E. 1986; New findings in live attenuated hepatitis A vaccine development. Journal of Medical Virology 19:23–31
    [Google Scholar]
  23. Provost P. J., Hughes J. V., Miller W. J., Giesa P. A., Banker F. S., Emini E. A. 1986; An inactivated hepatitis A viral vaccine of cell culture origin. Journal of Medical Virology 20:165–175
    [Google Scholar]
  24. Sambrook J., Fritsch E. F., Maniatis T. 1989 Molecular Cloning: A Laboratory Manual, 2nd. edn New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  25. Smith G. L., Murphy B. R., Moss B. 1983; Construction and characterization of a vaccinia virus recombinant that expresses the influenza virus hemagglutinin gene and induces resistance to infection in hamsters. Proceedings of the National Academy of Sciences, U.S.A 80:7155–7159
    [Google Scholar]
  26. Stapleton J. T., Lemon S. M. 1987; Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. Journal of Virology 61:491–498
    [Google Scholar]
  27. Ticehurst J. R., Feinstone S. M., Chestnut T., Tassopoulos N. C., Popper H., Purcell R. H. 1987; Detection of hepatitis A virus by extraction of viral RNA and molecular hybridization. Journal of Clinical Microbiology 25:1822–1829
    [Google Scholar]
  28. Wiktor T. J., MacFarlan R. I., Reagan K. J., Dietzschold B., Curtis P. J., Wunner W. H., Kieny M. P., Lathe R., Lecocq J. P., Mackett R. I., Moss B., Koprowski H. 1984; Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proceedings of the National Academy of Sciences, U.S.A 81:7194–7198
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-72-9-2167
Loading
/content/journal/jgv/10.1099/0022-1317-72-9-2167
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error